Status: Not yet recruiting
Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies
This study aims to observe the efficacy and safety of the combination of vebecotototo monoclonal antibody and putli monoclonal antibody in the treatment of EGFR-positive refractory biliary malignant tumors.
Participants needed: 49
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: West China HospitalUpdated: Jul 14, 2026Locations: 1
Eligibility criteria
Age 18 to 75 years, regardless of gender; [+11]
History of another malignant tumor diagnosed within the past 5 years (except car... [+12]